Atox Bio is a clinical stage biotechnology company that develops therapeutics for diseases mediated by a deregulated inflammatory response. Atox Bio focuses on novel modulators of the immune response that target key multiple and interrelated pathways of both the adaptive and innate immune response that play critical roles in infectious and inflammatory diseases as well as ischemia/reperfusion injuries.

AB103, Atox Bio’s lead clinical candidate, is being developed for severe bacterial infections including necrotizing soft tissue and intra-abdominal infections. A phase 2 study in patients with necrotizing soft tissue infection (NSTI) was initiated in December 2011.

In October 2011, the FDA has granted AB103 orphan drug status for NSTI.

Over $12m were granted for biodefense research by US Army, DARPA and NIAID for the development of therapeutics against a broad family of bacterial toxins, the superantigens.